



Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Lecture Presentation at the Digestive Diseases Week® 2018

March 19, 2018

CARMIEL, Israel, March 19, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that an abstract detailing the results from the Company's phase IIa clinical trial of OPRX-106 for the treatment of ulcerative colitis results has been accepted for a lecture presentation at the Digestive Disease Week® 2018 Annual Meeting in Washington, D.C. The lecture presentation titled "A novel orally administered recombinant anti-TNF alpha fusion protein for the treatment of mild to moderate ulcerative colitis: results of a Phase IIa clinical trial showing promising results" is scheduled to take place at 5:01 pm, ET, as part of a session entitled Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section Distinguished Abstract Plenary which is taking place on June 4, 2018 from 4:00 pm to 5:30 pm, ET. The conference is being held at the Walter E. Washington Convention Center in Washington, DC, June 2-5, 2018.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix's development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has entered into an ex-United States partnership with Chiesi Farmaceutici S.p.A. for the development and commercialization of pegunigalsidase alfa. Protalix maintains full rights to pegunigalsidase alfa in the United States.

Investor Contact

Marcy Nanus
Solebury Trout Group
646-378-2927
mnanus@troutgroup.com

Protalix BioTherapeutics, Inc.